title: Circulating catecholamine and potassium concentrations early in acute myocardial infarction: effect of intervention with timolol.
abstract: In a prospective study, 20 patients with a first acute myocardial infarction and no current treatment with diuretics or cardioactive drugs were randomized to treatment with intravenous timolol (10 patients) or placebo (10 patients). Plasma adrenaline, noradrenaline, and serum potassium were estimated at baseline (mean +/- SD 3.6 +/- 0.8 hours after the onset of the infarction) and 4 hours after the start of treatment. The patient selection criteria embraced a low-risk study population. Before treatment, the serum potassium concentrations correlated inversely with plasma adrenaline but not with plasma noradrenaline concentrations. A rise of serum potassium (mean +/- SD mmol/L) from 4.1 +/- 0.3 to 4.4 +/- 0.4 (p less than 0.05) in the placebo group and from 4.0 +/- 0.4 to 4.5 +/- 0.5 (p less than 0.05) in the timolol group was in multivariate analysis associated with infarct size, estimated as cumulative creatine kinase release, in the placebo group, and with the mean individual plasma adrenaline concentrations in the timolol group. By reversing the effect of adrenaline from a decrease to an increase in the serum potassium concentrations, timolol changes the relationships between circulating adrenaline, potassium, and infarct size.
mesh_terms: D000368:Aged; D003402:Creatine Kinase / Q000097:blood; D004837:Epinephrine / Q000097:blood*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood / Q000188:drug therapy*; D009638:Norepinephrine / Q000097:blood*; D011188:Potassium / Q000097:blood*; D011446:Prospective Studies; D013997:Time Factors; D013999:Timolol / Q000627:therapeutic use*
chemical_list: D013999:Timolol; D003402:Creatine Kinase; D011188:Potassium; D009638:Norepinephrine; D004837:Epinephrine